Breast Cancer

Key clinical point: Patients with breast cancer (BC) who underwent post-mastectomy breast reconstruction followed by post-mastectomy radiotherapy (PMRT) had an increased risk for postoperative complications, such as infections and contractures, than those who did not receive PMRT.

Major finding: Patients who did vs did not receive PMRT had a significantly higher risk for postoperative wound infections (odds ratio [OR] 1.95; P = .003) and skin contractures (OR 7.24; P = .005).

Study details: Findings are from a meta-analysis of 11 studies including 2288 patients with BC who underwent breast reconstruction, of which 516 patients received PMRT after breast reconstruction.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Huang N, Lu L, et al. Effect of radiation therapy during surgery on postoperative wound complications after breast reconstruction in patients with breast cancer: A meta-analysis. Int Wound J. 2023 (Oct 31). doi: 10.1111/iwj.14473

Key clinical point: Patients with breast cancer (BC) who underwent post-mastectomy breast reconstruction followed by post-mastectomy radiotherapy (PMRT) had an increased risk for postoperative complications, such as infections and contractures, than those who did not receive PMRT.

Major finding: Patients who did vs did not receive PMRT had a significantly higher risk for postoperative wound infections (odds ratio [OR] 1.95; P = .003) and skin contractures (OR 7.24; P = .005).

Study details: Findings are from a meta-analysis of 11 studies including 2288 patients with BC who underwent breast reconstruction, of which 516 patients received PMRT after breast reconstruction.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Huang N, Lu L, et al. Effect of radiation therapy during surgery on postoperative wound complications after breast reconstruction in patients with breast cancer: A meta-analysis. Int Wound J. 2023 (Oct 31). doi: 10.1111/iwj.14473

Key clinical point: Patients with breast cancer (BC) who underwent post-mastectomy breast reconstruction followed by post-mastectomy radiotherapy (PMRT) had an increased risk for postoperative complications, such as infections and contractures, than those who did not receive PMRT.

Major finding: Patients who did vs did not receive PMRT had a significantly higher risk for postoperative wound infections (odds ratio [OR] 1.95; P = .003) and skin contractures (OR 7.24; P = .005).

Study details: Findings are from a meta-analysis of 11 studies including 2288 patients with BC who underwent breast reconstruction, of which 516 patients received PMRT after breast reconstruction.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Huang N, Lu L, et al. Effect of radiation therapy during surgery on postoperative wound complications after breast reconstruction in patients with breast cancer: A meta-analysis. Int Wound J. 2023 (Oct 31). doi: 10.1111/iwj.14473

Key clinical point: Robotic nipple-sparing mastectomy (RNSM) may soon become a viable option for breast cancer (BC) surgery as it is associated with lower postoperative complication rates than conventional NSM (CNSM).

Major finding: RNSM vs CNSM was associated with a significantly lower rate of nipple necrosis, a major postoperative complication (odds ratio 0.54; P = .03), and intraoperative blood loss (mean difference [MD] −53.18 mL; P < .00001), but a significantly higher operating time (MD +58.81 min; P < .001).

Study details: Findings are from a meta-analysis of seven studies including 1674 women with BC who underwent RNSM (50.9%) or CNSM (49.1%).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Nessa A et al. Postoperative complications and surgical outcomes of robotic versus conventional nipple-sparing mastectomy in breast cancer: Meta-analysis. Br J Surg. 2023 (Oct 27). doi: 10.1093/bjs/znad336

Key clinical point: Robotic nipple-sparing mastectomy (RNSM) may soon become a viable option for breast cancer (BC) surgery as it is associated with lower postoperative complication rates than conventional NSM (CNSM).

Major finding: RNSM vs CNSM was associated with a significantly lower rate of nipple necrosis, a major postoperative complication (odds ratio 0.54; P = .03), and intraoperative blood loss (mean difference [MD] −53.18 mL; P < .00001), but a significantly higher operating time (MD +58.81 min; P < .001).

Study details: Findings are from a meta-analysis of seven studies including 1674 women with BC who underwent RNSM (50.9%) or CNSM (49.1%).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Nessa A et al. Postoperative complications and surgical outcomes of robotic versus conventional nipple-sparing mastectomy in breast cancer: Meta-analysis. Br J Surg. 2023 (Oct 27). doi: 10.1093/bjs/znad336

Key clinical point: Robotic nipple-sparing mastectomy (RNSM) may soon become a viable option for breast cancer (BC) surgery as it is associated with lower postoperative complication rates than conventional NSM (CNSM).

Major finding: RNSM vs CNSM was associated with a significantly lower rate of nipple necrosis, a major postoperative complication (odds ratio 0.54; P = .03), and intraoperative blood loss (mean difference [MD] −53.18 mL; P < .00001), but a significantly higher operating time (MD +58.81 min; P < .001).

Study details: Findings are from a meta-analysis of seven studies including 1674 women with BC who underwent RNSM (50.9%) or CNSM (49.1%).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Nessa A et al. Postoperative complications and surgical outcomes of robotic versus conventional nipple-sparing mastectomy in breast cancer: Meta-analysis. Br J Surg. 2023 (Oct 27). doi: 10.1093/bjs/znad336

Key clinical point: Adjuvant chemotherapy significantly improved the overall survival (OS) outcomes in patients with small-size (T1b and T1c) node-negative triple-negative breast cancer (TNBC).

Major finding: Adjuvant chemotherapy led to significantly better OS outcomes in patients with T1b TNBC (adjusted hazard ratio [aHR] 0.52; P < .001) and improved both OS (aHR 0.54; P < .001) and breast cancer-specific survival (aHR 0.79; P = .043) in those with T1c TNBC.

Study details: This retrospective study analyzed the data from the Surveillance, Epidemiology, and End Results (SEER) database and included 11,510 women with T1b (n = 3388) or T1c (n = 8122) node-negative TNBC, of whom 8029 patients received adjuvant chemotherapy.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Carbajal-Ochoa W et al. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer. Breast Cancer Res Treat. 2023 (Oct 13). doi: 10.1007/s10549-023-07132-6

Key clinical point: Adjuvant chemotherapy significantly improved the overall survival (OS) outcomes in patients with small-size (T1b and T1c) node-negative triple-negative breast cancer (TNBC).

Major finding: Adjuvant chemotherapy led to significantly better OS outcomes in patients with T1b TNBC (adjusted hazard ratio [aHR] 0.52; P < .001) and improved both OS (aHR 0.54; P < .001) and breast cancer-specific survival (aHR 0.79; P = .043) in those with T1c TNBC.

Study details: This retrospective study analyzed the data from the Surveillance, Epidemiology, and End Results (SEER) database and included 11,510 women with T1b (n = 3388) or T1c (n = 8122) node-negative TNBC, of whom 8029 patients received adjuvant chemotherapy.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Carbajal-Ochoa W et al. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer. Breast Cancer Res Treat. 2023 (Oct 13). doi: 10.1007/s10549-023-07132-6

Key clinical point: Adjuvant chemotherapy significantly improved the overall survival (OS) outcomes in patients with small-size (T1b and T1c) node-negative triple-negative breast cancer (TNBC).

Major finding: Adjuvant chemotherapy led to significantly better OS outcomes in patients with T1b TNBC (adjusted hazard ratio [aHR] 0.52; P < .001) and improved both OS (aHR 0.54; P < .001) and breast cancer-specific survival (aHR 0.79; P = .043) in those with T1c TNBC.

Study details: This retrospective study analyzed the data from the Surveillance, Epidemiology, and End Results (SEER) database and included 11,510 women with T1b (n = 3388) or T1c (n = 8122) node-negative TNBC, of whom 8029 patients received adjuvant chemotherapy.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Carbajal-Ochoa W et al. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer. Breast Cancer Res Treat. 2023 (Oct 13). doi: 10.1007/s10549-023-07132-6

Key clinical point: Pregnancy had no detrimental effects on survival outcomes and can be considered safe for young women who were previously diagnosed with and underwent treatment for hormone receptor-positive (HR+) early breast cancer (BC).

Major finding: Patients with a history of HR+ BC who did vs did not conceive after treatment showed better overall survival outcomes (hazard ratio 0.46; P < .005); however, the disease-free survival outcomes were comparable for both groups (P = .781).

Study details: Findings are from a meta-analysis of eight retrospective cohort studies including 3805 young women with HR+ invasive early BC, of whom 1285 women conceived post treatment.

Disclosures: This study was partially supported by the Italian Association for Cancer Research and the Italian Ministry of Health. Several authors declared receiving research support, honoraria, research funding, personal fees, grants, or consulting fees from or having ties with various sources.

Source: Arecco L et al. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: A systematic review and meta-analysis. ESMO Open. 2023;8(6):102031 (Oct 23). doi: 10.1016/j.esmoop.2023.102031

Key clinical point: Pregnancy had no detrimental effects on survival outcomes and can be considered safe for young women who were previously diagnosed with and underwent treatment for hormone receptor-positive (HR+) early breast cancer (BC).

Major finding: Patients with a history of HR+ BC who did vs did not conceive after treatment showed better overall survival outcomes (hazard ratio 0.46; P < .005); however, the disease-free survival outcomes were comparable for both groups (P = .781).

Study details: Findings are from a meta-analysis of eight retrospective cohort studies including 3805 young women with HR+ invasive early BC, of whom 1285 women conceived post treatment.

Disclosures: This study was partially supported by the Italian Association for Cancer Research and the Italian Ministry of Health. Several authors declared receiving research support, honoraria, research funding, personal fees, grants, or consulting fees from or having ties with various sources.

Source: Arecco L et al. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: A systematic review and meta-analysis. ESMO Open. 2023;8(6):102031 (Oct 23). doi: 10.1016/j.esmoop.2023.102031

Key clinical point: Pregnancy had no detrimental effects on survival outcomes and can be considered safe for young women who were previously diagnosed with and underwent treatment for hormone receptor-positive (HR+) early breast cancer (BC).

Major finding: Patients with a history of HR+ BC who did vs did not conceive after treatment showed better overall survival outcomes (hazard ratio 0.46; P < .005); however, the disease-free survival outcomes were comparable for both groups (P = .781).

Study details: Findings are from a meta-analysis of eight retrospective cohort studies including 3805 young women with HR+ invasive early BC, of whom 1285 women conceived post treatment.

Disclosures: This study was partially supported by the Italian Association for Cancer Research and the Italian Ministry of Health. Several authors declared receiving research support, honoraria, research funding, personal fees, grants, or consulting fees from or having ties with various sources.

Source: Arecco L et al. Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: A systematic review and meta-analysis. ESMO Open. 2023;8(6):102031 (Oct 23). doi: 10.1016/j.esmoop.2023.102031

Key clinical point: Detection of breast cancer (BC) by screening vs clinical or other non-screening procedures led to significantly improved disease-free interval outcomes.

Major finding: After correcting for lead time bias, the 10-year disease-free interval was improved significantly in women with screen-detected vs clinically-detected cancer (adjusted hazard ratio [aHR] 0.77; 95% CI 0.68-0.87), with similar improvements observed in 5-year disease-free interval in women with screen-detected vs non-screen-related cancer (aHR 0.76; 95% CI 0.66-0.88).

Study details: Findings are from an analysis of two cohorts including 6215 and 15,176 women with invasive, non-metastatic BC who underwent surgery and were followed for 10 and 5 years, respectively, of which 55.8% of women in either of the cohorts had a screen-detected cancer.

Disclosures: This study did not declare any specific funding. S Siesling declared receiving support and serving as an advisor for various sources. The other authors declared no conflicts of interest.

Source: de Munck L et al. Method of primary breast cancer detection and the disease-free interval, adjusting for lead time. J Natl Cancer Inst. 2023 (Nov 3). doi: 10.1093/jnci/djad230

Key clinical point: Detection of breast cancer (BC) by screening vs clinical or other non-screening procedures led to significantly improved disease-free interval outcomes.

Major finding: After correcting for lead time bias, the 10-year disease-free interval was improved significantly in women with screen-detected vs clinically-detected cancer (adjusted hazard ratio [aHR] 0.77; 95% CI 0.68-0.87), with similar improvements observed in 5-year disease-free interval in women with screen-detected vs non-screen-related cancer (aHR 0.76; 95% CI 0.66-0.88).

Study details: Findings are from an analysis of two cohorts including 6215 and 15,176 women with invasive, non-metastatic BC who underwent surgery and were followed for 10 and 5 years, respectively, of which 55.8% of women in either of the cohorts had a screen-detected cancer.

Disclosures: This study did not declare any specific funding. S Siesling declared receiving support and serving as an advisor for various sources. The other authors declared no conflicts of interest.

Source: de Munck L et al. Method of primary breast cancer detection and the disease-free interval, adjusting for lead time. J Natl Cancer Inst. 2023 (Nov 3). doi: 10.1093/jnci/djad230

Key clinical point: Detection of breast cancer (BC) by screening vs clinical or other non-screening procedures led to significantly improved disease-free interval outcomes.

Major finding: After correcting for lead time bias, the 10-year disease-free interval was improved significantly in women with screen-detected vs clinically-detected cancer (adjusted hazard ratio [aHR] 0.77; 95% CI 0.68-0.87), with similar improvements observed in 5-year disease-free interval in women with screen-detected vs non-screen-related cancer (aHR 0.76; 95% CI 0.66-0.88).

Study details: Findings are from an analysis of two cohorts including 6215 and 15,176 women with invasive, non-metastatic BC who underwent surgery and were followed for 10 and 5 years, respectively, of which 55.8% of women in either of the cohorts had a screen-detected cancer.

Disclosures: This study did not declare any specific funding. S Siesling declared receiving support and serving as an advisor for various sources. The other authors declared no conflicts of interest.

Source: de Munck L et al. Method of primary breast cancer detection and the disease-free interval, adjusting for lead time. J Natl Cancer Inst. 2023 (Nov 3). doi: 10.1093/jnci/djad230

Key clinical point: Although local transdermal therapy with 4-hydroxytamoxifen was associated with low systemic exposure, it was not as effective as oral tamoxifen in suppressing proliferation in the ductal carcinoma in situ (DCIS) lesions of the breast.

Major finding: Posttreatment Ki67 labelling index was significantly higher in the transdermal 4-hydroxytamoxifen gel vs oral tamoxifen treatment group (3.3%; 80% CI 2.1%-4.6%), with the value exceeding the noninferiority margin of 2.6%. Grade 2 adverse events were reported by five patients in both groups.

Study details: Findings are from a phase 2 study including 107 patients with DCIS of the breast who were randomly assigned to receive oral tamoxifen or 4-hydroxytamoxifen gel treatment for 4-10 weeks, of which 90 patients completed the treatment and underwent surgery.

Disclosures: This trial was sponsored by the US National Cancer Institute. Some authors declared receiving grant funding from various sources or holding a patent.

Source: Khan SA et al. Presurgical oral tamoxifen vs transdermal 4-hydroxytamoxifen in women with ductal carcinoma in situ: A randomized clinical trial. JAMA Surg. 2023 (Oct 23). doi: 10.1001/jamasurg.2023.5113

Key clinical point: Although local transdermal therapy with 4-hydroxytamoxifen was associated with low systemic exposure, it was not as effective as oral tamoxifen in suppressing proliferation in the ductal carcinoma in situ (DCIS) lesions of the breast.

Major finding: Posttreatment Ki67 labelling index was significantly higher in the transdermal 4-hydroxytamoxifen gel vs oral tamoxifen treatment group (3.3%; 80% CI 2.1%-4.6%), with the value exceeding the noninferiority margin of 2.6%. Grade 2 adverse events were reported by five patients in both groups.

Study details: Findings are from a phase 2 study including 107 patients with DCIS of the breast who were randomly assigned to receive oral tamoxifen or 4-hydroxytamoxifen gel treatment for 4-10 weeks, of which 90 patients completed the treatment and underwent surgery.

Disclosures: This trial was sponsored by the US National Cancer Institute. Some authors declared receiving grant funding from various sources or holding a patent.

Source: Khan SA et al. Presurgical oral tamoxifen vs transdermal 4-hydroxytamoxifen in women with ductal carcinoma in situ: A randomized clinical trial. JAMA Surg. 2023 (Oct 23). doi: 10.1001/jamasurg.2023.5113

Key clinical point: Although local transdermal therapy with 4-hydroxytamoxifen was associated with low systemic exposure, it was not as effective as oral tamoxifen in suppressing proliferation in the ductal carcinoma in situ (DCIS) lesions of the breast.

Major finding: Posttreatment Ki67 labelling index was significantly higher in the transdermal 4-hydroxytamoxifen gel vs oral tamoxifen treatment group (3.3%; 80% CI 2.1%-4.6%), with the value exceeding the noninferiority margin of 2.6%. Grade 2 adverse events were reported by five patients in both groups.

Study details: Findings are from a phase 2 study including 107 patients with DCIS of the breast who were randomly assigned to receive oral tamoxifen or 4-hydroxytamoxifen gel treatment for 4-10 weeks, of which 90 patients completed the treatment and underwent surgery.

Disclosures: This trial was sponsored by the US National Cancer Institute. Some authors declared receiving grant funding from various sources or holding a patent.

Source: Khan SA et al. Presurgical oral tamoxifen vs transdermal 4-hydroxytamoxifen in women with ductal carcinoma in situ: A randomized clinical trial. JAMA Surg. 2023 (Oct 23). doi: 10.1001/jamasurg.2023.5113

Key clinical point: Pyrotinib+trastuzumab+docetaxel was more effective than placebo+trastuzumab+docetaxel in improving progression-free survival (PFS) outcomes and showed a manageable safety profile in patients with untreated human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).

Major finding: PFS improved by 59% with pyrotinib+trastuzumab+docetaxel vs placebo+trastuzumab+docetaxel treatment (24.3 vs 10.4 months; hazard ratio 0.41; stratified 1-sided P < .001). The most frequently reported grade ≥3 adverse events in the pyrotinib vs placebo treatment arm were decreased neutrophil count (63% vs 65%), decreased white blood cell count (53% vs 51%), and diarrhea (46% vs 3%).

Study details: Findings are from the phase 3 PHILA trial including 590 female patients with untreated HER2+ metastatic BC who were randomly assigned to receive pyrotinib or placebo, both in combination with trastuzumab and docetaxel.

Disclosures: This study was funded by Jiangsu Hengrui Pharmaceuticals, China, and other sources. Three authors declared being employees of Jiangsu Hengrui Pharmaceuticals, and two other authors reported ties with various sources.

Source: Ma F et al, on behalf of the PHILA Investigators. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): Randomised, double blind, multicentre, phase 3 trial. BMJ. 2023;383:e076065 (Oct 31). doi: 10.1136/bmj-2023-076065

Key clinical point: Pyrotinib+trastuzumab+docetaxel was more effective than placebo+trastuzumab+docetaxel in improving progression-free survival (PFS) outcomes and showed a manageable safety profile in patients with untreated human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).

Major finding: PFS improved by 59% with pyrotinib+trastuzumab+docetaxel vs placebo+trastuzumab+docetaxel treatment (24.3 vs 10.4 months; hazard ratio 0.41; stratified 1-sided P < .001). The most frequently reported grade ≥3 adverse events in the pyrotinib vs placebo treatment arm were decreased neutrophil count (63% vs 65%), decreased white blood cell count (53% vs 51%), and diarrhea (46% vs 3%).

Study details: Findings are from the phase 3 PHILA trial including 590 female patients with untreated HER2+ metastatic BC who were randomly assigned to receive pyrotinib or placebo, both in combination with trastuzumab and docetaxel.

Disclosures: This study was funded by Jiangsu Hengrui Pharmaceuticals, China, and other sources. Three authors declared being employees of Jiangsu Hengrui Pharmaceuticals, and two other authors reported ties with various sources.

Source: Ma F et al, on behalf of the PHILA Investigators. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): Randomised, double blind, multicentre, phase 3 trial. BMJ. 2023;383:e076065 (Oct 31). doi: 10.1136/bmj-2023-076065

Key clinical point: Pyrotinib+trastuzumab+docetaxel was more effective than placebo+trastuzumab+docetaxel in improving progression-free survival (PFS) outcomes and showed a manageable safety profile in patients with untreated human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC).

Major finding: PFS improved by 59% with pyrotinib+trastuzumab+docetaxel vs placebo+trastuzumab+docetaxel treatment (24.3 vs 10.4 months; hazard ratio 0.41; stratified 1-sided P < .001). The most frequently reported grade ≥3 adverse events in the pyrotinib vs placebo treatment arm were decreased neutrophil count (63% vs 65%), decreased white blood cell count (53% vs 51%), and diarrhea (46% vs 3%).

Study details: Findings are from the phase 3 PHILA trial including 590 female patients with untreated HER2+ metastatic BC who were randomly assigned to receive pyrotinib or placebo, both in combination with trastuzumab and docetaxel.

Disclosures: This study was funded by Jiangsu Hengrui Pharmaceuticals, China, and other sources. Three authors declared being employees of Jiangsu Hengrui Pharmaceuticals, and two other authors reported ties with various sources.

Source: Ma F et al, on behalf of the PHILA Investigators. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): Randomised, double blind, multicentre, phase 3 trial. BMJ. 2023;383:e076065 (Oct 31). doi: 10.1136/bmj-2023-076065

Key clinical point: Regional node radiotherapy improved breast cancer (BC) mortality rates in women with early-stage BC who had received other effective local and systemic therapies.

Major finding: Regional node radiotherapy reduced the risk for overall BC recurrence and mortality by 10% (rate ratio [RR] 0.90; P = .0020) and 9% (RR 0.91; P = .012), respectively. In the newer trials that assessed more tailored radiotherapy approaches, a more prominent reduction was observed in the overall BC recurrence (RR 0.88; P = .00083) and mortality (RR 0.87; P = .0010) rates along with 10% improvement in overall mortality (P = .0022).

Study details: Findings are from a meta-analysis of 16 trials including 14,324 patients with early BC, with 8 of the 16 trials being newer and including 12,167 patients.

Disclosures: This study was funded by Cancer Research UK and the UK Medical Research Council. Some authors declared receiving institutional grants, honoraria, payments, or research funding from and having other ties with several sources.

Source: Early Breast Cancer Trialists' Collaborative Group. Radiotherapy to regional nodes in early breast cancer: An individual patient data meta-analysis of 14 324 women in 16 trials. Lancet. 2023 (Nov 3). doi: 10.1016/S0140-6736(23)01082-6

Key clinical point: Regional node radiotherapy improved breast cancer (BC) mortality rates in women with early-stage BC who had received other effective local and systemic therapies.

Major finding: Regional node radiotherapy reduced the risk for overall BC recurrence and mortality by 10% (rate ratio [RR] 0.90; P = .0020) and 9% (RR 0.91; P = .012), respectively. In the newer trials that assessed more tailored radiotherapy approaches, a more prominent reduction was observed in the overall BC recurrence (RR 0.88; P = .00083) and mortality (RR 0.87; P = .0010) rates along with 10% improvement in overall mortality (P = .0022).

Study details: Findings are from a meta-analysis of 16 trials including 14,324 patients with early BC, with 8 of the 16 trials being newer and including 12,167 patients.

Disclosures: This study was funded by Cancer Research UK and the UK Medical Research Council. Some authors declared receiving institutional grants, honoraria, payments, or research funding from and having other ties with several sources.

Source: Early Breast Cancer Trialists' Collaborative Group. Radiotherapy to regional nodes in early breast cancer: An individual patient data meta-analysis of 14 324 women in 16 trials. Lancet. 2023 (Nov 3). doi: 10.1016/S0140-6736(23)01082-6

Key clinical point: Regional node radiotherapy improved breast cancer (BC) mortality rates in women with early-stage BC who had received other effective local and systemic therapies.

Major finding: Regional node radiotherapy reduced the risk for overall BC recurrence and mortality by 10% (rate ratio [RR] 0.90; P = .0020) and 9% (RR 0.91; P = .012), respectively. In the newer trials that assessed more tailored radiotherapy approaches, a more prominent reduction was observed in the overall BC recurrence (RR 0.88; P = .00083) and mortality (RR 0.87; P = .0010) rates along with 10% improvement in overall mortality (P = .0022).

Study details: Findings are from a meta-analysis of 16 trials including 14,324 patients with early BC, with 8 of the 16 trials being newer and including 12,167 patients.

Disclosures: This study was funded by Cancer Research UK and the UK Medical Research Council. Some authors declared receiving institutional grants, honoraria, payments, or research funding from and having other ties with several sources.

Source: Early Breast Cancer Trialists' Collaborative Group. Radiotherapy to regional nodes in early breast cancer: An individual patient data meta-analysis of 14 324 women in 16 trials. Lancet. 2023 (Nov 3). doi: 10.1016/S0140-6736(23)01082-6

Key clinical point: Obesity increased the risk for recurrence in postmenopausal women with early-stage hormone receptor-positive (HR+) breast cancer (BC) who were treated with aromatase inhibitors (AI).

Major finding: Among patients with AI-treated HR+ BC, the risk for BC recurrence was significantly higher in those with obesity (adjusted hazard ratio [aHR] 1.18; 95% CI 1.01-1.37) and severe obesity (aHR 1.32; 95% CI 1.08-1.62) than in those with a healthy weight.

Study details: Findings are from a nationwide cohort study including 13,230 postmenopausal women with stages I-III HR+ BC who received AI.

Disclosures: This study was supported by the Jeppe Juhl Memorial Foundation, Denmark, and other Danish sources. Jensen MR declared receiving from Novartis meeting expenses and personal fees unrelated to this study.

Source: Harborg S et al. Obesity and risk of recurrence in patients with breast cancer treated with aromatase inhibitors. JAMA Netw Open. 2023;6(10):e2337780 (Oct 13). doi: 10.1001/jamanetworkopen.2023.37780

Key clinical point: Obesity increased the risk for recurrence in postmenopausal women with early-stage hormone receptor-positive (HR+) breast cancer (BC) who were treated with aromatase inhibitors (AI).

Major finding: Among patients with AI-treated HR+ BC, the risk for BC recurrence was significantly higher in those with obesity (adjusted hazard ratio [aHR] 1.18; 95% CI 1.01-1.37) and severe obesity (aHR 1.32; 95% CI 1.08-1.62) than in those with a healthy weight.

Study details: Findings are from a nationwide cohort study including 13,230 postmenopausal women with stages I-III HR+ BC who received AI.

Disclosures: This study was supported by the Jeppe Juhl Memorial Foundation, Denmark, and other Danish sources. Jensen MR declared receiving from Novartis meeting expenses and personal fees unrelated to this study.

Source: Harborg S et al. Obesity and risk of recurrence in patients with breast cancer treated with aromatase inhibitors. JAMA Netw Open. 2023;6(10):e2337780 (Oct 13). doi: 10.1001/jamanetworkopen.2023.37780

Key clinical point: Obesity increased the risk for recurrence in postmenopausal women with early-stage hormone receptor-positive (HR+) breast cancer (BC) who were treated with aromatase inhibitors (AI).

Major finding: Among patients with AI-treated HR+ BC, the risk for BC recurrence was significantly higher in those with obesity (adjusted hazard ratio [aHR] 1.18; 95% CI 1.01-1.37) and severe obesity (aHR 1.32; 95% CI 1.08-1.62) than in those with a healthy weight.

Study details: Findings are from a nationwide cohort study including 13,230 postmenopausal women with stages I-III HR+ BC who received AI.

Disclosures: This study was supported by the Jeppe Juhl Memorial Foundation, Denmark, and other Danish sources. Jensen MR declared receiving from Novartis meeting expenses and personal fees unrelated to this study.

Source: Harborg S et al. Obesity and risk of recurrence in patients with breast cancer treated with aromatase inhibitors. JAMA Netw Open. 2023;6(10):e2337780 (Oct 13). doi: 10.1001/jamanetworkopen.2023.37780

Key clinical point: Capecitabine-based chemotherapy improved prognostic outcomes in patients with early-stage triple-negative breast cancer (TNBC).

Major finding: Capecitabine-based chemotherapy vs capecitabine-free regimens improved disease-free survival (DFS; hazard ratio [HR] 0.81; P < .001) and overall survival (HR 0.75; P < .001) outcomes. DFS benefits were particularly observed in the adjuvant setting (HR 0.79; P < .001) and in the subgroup of patients with lymph node-negative TNBC (HR 0.68; P  =  .006) and in those who received capecitabine for ≥ 6 cycles (HR 0.71; P < .001).

Study details: Findings are from a meta-analysis of 12 randomized controlled trials including 5390 patients with TNBC who were treated with capecitabine-based chemotherapy or capecitabine-free regimens.

Disclosures: This study was supported by the National Natural Science Foundation of China and the Natural Science Foundation of Chongqing. The authors declared no conflicts of interest.

Source: Bai J et al. Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: A meta-analysis. Front Oncol. 2023;13:1245650 (Oct 25). doi: 10.3389/fonc.2023.1245650

Key clinical point: Capecitabine-based chemotherapy improved prognostic outcomes in patients with early-stage triple-negative breast cancer (TNBC).

Major finding: Capecitabine-based chemotherapy vs capecitabine-free regimens improved disease-free survival (DFS; hazard ratio [HR] 0.81; P < .001) and overall survival (HR 0.75; P < .001) outcomes. DFS benefits were particularly observed in the adjuvant setting (HR 0.79; P < .001) and in the subgroup of patients with lymph node-negative TNBC (HR 0.68; P  =  .006) and in those who received capecitabine for ≥ 6 cycles (HR 0.71; P < .001).

Study details: Findings are from a meta-analysis of 12 randomized controlled trials including 5390 patients with TNBC who were treated with capecitabine-based chemotherapy or capecitabine-free regimens.

Disclosures: This study was supported by the National Natural Science Foundation of China and the Natural Science Foundation of Chongqing. The authors declared no conflicts of interest.

Source: Bai J et al. Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: A meta-analysis. Front Oncol. 2023;13:1245650 (Oct 25). doi: 10.3389/fonc.2023.1245650

Key clinical point: Capecitabine-based chemotherapy improved prognostic outcomes in patients with early-stage triple-negative breast cancer (TNBC).

Major finding: Capecitabine-based chemotherapy vs capecitabine-free regimens improved disease-free survival (DFS; hazard ratio [HR] 0.81; P < .001) and overall survival (HR 0.75; P < .001) outcomes. DFS benefits were particularly observed in the adjuvant setting (HR 0.79; P < .001) and in the subgroup of patients with lymph node-negative TNBC (HR 0.68; P  =  .006) and in those who received capecitabine for ≥ 6 cycles (HR 0.71; P < .001).

Study details: Findings are from a meta-analysis of 12 randomized controlled trials including 5390 patients with TNBC who were treated with capecitabine-based chemotherapy or capecitabine-free regimens.

Disclosures: This study was supported by the National Natural Science Foundation of China and the Natural Science Foundation of Chongqing. The authors declared no conflicts of interest.

Source: Bai J et al. Capecitabine-based chemotherapy in early-stage triple-negative breast cancer: A meta-analysis. Front Oncol. 2023;13:1245650 (Oct 25). doi: 10.3389/fonc.2023.1245650